Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.

@article{Jong1998PreclinicalCO,
  title={Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.},
  author={Marion de Jong and Willem H. Bakker and Wouter A. P. Breeman and Bert F. Bernard and Leo J. Hofland and Theo J. Visser and Ananth Srinivasan and Michelle A. Schmidt and Martin B{\'e}h{\'e} and Helmut R. Maecke and Eric P. Krenning},
  journal={International journal of cancer},
  year={1998},
  volume={75 3},
  pages={406-11}
}
We have evaluated the potential usefulness of radiolabelled [DTPA0,Tyr3]octreotide and [DOTA0,Tyr3]octreotide as radiopharmaceuticals for somatostatin receptor-targeted scintigraphy and radiotherapy. In vitro somatostatin receptor binding and in vivo metabolism in rats of the compounds were investigated in comparison with [111In-DTPA0] octreotide. Comparing different peptide-chelator constructs, [DTPA0,Tyr3]octreotide and [DOTA0,Tyr3]octreotide were found to have a higher affinity than [DTPA0… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…